Literature DB >> 25645844

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Helio S Sader1, Robert K Flamm2, Jennifer M Streit2, David J Farrell2, Ronald N Jones2.   

Abstract

A total of 84,704 isolates were collected from 191 medical centers in 2009 to 2013 and tested for susceptibility to ceftaroline and comparator agents by broth microdilution methods. Ceftaroline inhibited all Staphylococcus aureus isolates at ≤2 μg/ml and was very active against methicillin-resistant strains (MIC at which 90% of the isolates tested are inhibited [MIC90], 1 μg/ml; 97.6% susceptible). Among Streptococcus pneumoniae isolates, the highest ceftaroline MIC was 0.5 μg/ml, and ceftaroline activity against the most common Enterobacteriaceae species (MIC50, 0.12 μg/ml; 78.9% susceptible) was similar to that of ceftriaxone (MIC50, ≤0.25 μg/ml; 86.8% susceptible).
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25645844      PMCID: PMC4356765          DOI: 10.1128/AAC.04614-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Prevalence of β-lactamase-encoding genes among Enterobacteriaceae bacteremia isolates collected in 26 U.S. hospitals: report from the SENTRY Antimicrobial Surveillance Program (2010).

Authors:  Mariana Castanheira; Sarah E Farrell; Lalitagauri M Deshpande; Rodrigo E Mendes; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

2.  Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Authors:  Rodrigo E Mendes; Andrew J Costello; Michael R Jacobs; Donald Biek; Ian A Critchley; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-05-24       Impact factor: 2.803

3.  Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).

Authors:  Michael A Pfaller; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2014-01-18       Impact factor: 2.803

4.  Pharmacodynamics of ceftaroline fosamil for complicated skin and skin structure infection: rationale for improved anti-methicillin-resistant Staphylococcus aureus activity.

Authors:  George L Drusano
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

5.  Affinity of ceftaroline and other beta-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae.

Authors:  K Kosowska-Shick; P L McGhee; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2010-03-01       Impact factor: 5.191

6.  Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

Authors:  G Ralph Corey; Mark Wilcox; George H Talbot; H David Friedland; Tanya Baculik; Gary W Witherell; Ian Critchley; Anita F Das; Dirk Thye
Journal:  Clin Infect Dis       Date:  2010-09-15       Impact factor: 9.079

Review 7.  In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).

Authors:  David J Farrell; Mariana Castanheira; Rodrigo E Mendes; Helio S Sader; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2012-09       Impact factor: 9.079

8.  Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

9.  Contemporary diversity of β-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent β-lactamase groups.

Authors:  Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

10.  Ceftaroline fosamil: a brief clinical review.

Authors:  Debbie-Ann T Shirley; Emily L Heil; J Kristie Johnson
Journal:  Infect Dis Ther       Date:  2013-08-08
View more
  8 in total

1.  Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia.

Authors:  I J Abbott; A W J Jenney; C J Jeremiah; M Mirčeta; J P Kandiah; D C Holt; S Y C Tong; D W Spelman
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

2.  Antimicrobial Activities of Ceftaroline and Comparator Agents against Bacterial Organisms Causing Bacteremia in Patients with Skin and Skin Structure Infections in U.S. Medical Centers, 2008 to 2014.

Authors:  Helio S Sader; Robert K Flamm; Rodrigo E Mendes; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

3.  Incidence and risk factors for mortality in patients treated with combined ceftaroline for Gram-positive infective endocarditis.

Authors:  D Brandariz-Núñez; J Suanzes; J M Gutiérrez-Urbón; C Fernández-Oliveira; L Margusino; I Martín-Herranz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-04-18       Impact factor: 3.267

Review 4.  Use of Ceftaroline Fosamil in Children: Review of Current Knowledge and its Application.

Authors:  Juwon Yim; Leah M Molloy; Jason G Newland
Journal:  Infect Dis Ther       Date:  2016-12-30

5.  Antibiotic Resistance Rates by Geographic Region Among Ocular Pathogens Collected During the ARMOR Surveillance Study.

Authors:  Penny A Asbell; Rahul T Pandit; Christine M Sanfilippo
Journal:  Ophthalmol Ther       Date:  2018-08-09

6.  In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.

Authors:  Peiyao Jia; Ying Zhu; Hui Zhang; Bin Cheng; Ping Guo; Yingchun Xu; Qiwen Yang
Journal:  BMC Microbiol       Date:  2022-10-01       Impact factor: 4.465

7.  Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.

Authors:  Tiffany R Keepers; Marcela Gomez; Chris Celeri; Kevin M Krause; Donald Biek; Ian Critchley
Journal:  Infect Dis Ther       Date:  2017-03-11

8.  Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime-avibactam: a surveillance study from the ATLAS program (2012-2016).

Authors:  Hui Zhang; Yingchun Xu; Peiyao Jia; Ying Zhu; Ge Zhang; Jingjia Zhang; Simeng Duan; Wei Kang; Tong Wang; Ran Jing; Jingwei Cheng; Yali Liu; Qiwen Yang
Journal:  Antimicrob Resist Infect Control       Date:  2020-10-27       Impact factor: 4.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.